Skip to main content

Innova Captab Ltd

NSE: INNOVACAP BSE: 544067Pharma

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

878
52W: ₹608 — ₹1021
PE 60 · Book ₹155 · +466% vs book
Market Cap₹5,023 Cr
Stock P/E60Price to Earnings
ROCE10.8%Return on Capital
ROE9.85%Return on Equity
Div. Yield0.23%Face Value ₹10

Strengths

  • +Company is expected to give good quarter

Weaknesses

  • Stock is trading at 5.74 times its book value
  • Company has a low return on equity of 11.5% over last 3 years.
  • Company might be capitalizing the interest cost

Shareholding Pattern

Promoters50.9%
FIIs0.23%
DIIs20.14%
Public28.74%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters50.9%50.9%50.9%50.9%50.9%50.9%50.9%50.9%
FIIs1.19%1.01%0.20.74%0.30.35%0.40.23%0.10.08%0.20.1%0.00.23%0.1
DIIs21.24%20.61%0.619.96%0.619.77%0.219.67%0.120.17%0.520.24%0.120.14%0.1
Public26.67%27.48%0.828.41%0.929%0.629.2%0.228.86%0.328.76%0.128.74%0.0

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales236198227240249243287290364358
Expenses206175198207216214252260317320
Operating Profit31232833322835294739
OPM %13%12%13%14%13%12%12%10%13%11%
Net Profit19202226241720142821
EPS ₹3.263.453.94.484.262.993.552.54.883.7

AI Insights

Revenue Trend

Mar 2026 revenue at ₹1,299Cr, up 35.6% YoY. OPM at 12%.

Debt Position

Borrowings at ₹321Cr. Debt-to-equity ratio: 0.39x. Healthy balance sheet.

Capex Cycle

CWIP at ₹15Cr (2% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 20.14% (+9.83pp change). FIIs: 0.23% (-3.34pp change). Promoters hold 50.9%.

Margin & Efficiency

ROCE improving from 0% (Mar 2020) to 11% (Mar 2026). Working capital days: 94.

Valuation

PE 60x with 10.8% ROCE. Price is 466% above book value of ₹155. Dividend yield: 0.23%.

Recent Announcements